Drug costs vary by more than 600% in study of 10 high-income countries
Advertisement
In a study of 10 high-income countries with universal health care, costs for prescription drugs in 6 of the largest categories of primary care medicines varied by more than 600%. All countries except Canada offered universal coverage of outpatient prescription drugs.
jarmoluk; pixabay.com; CC0
The study looked at data on the volume and daily cost of primary care prescriptions in 10 high-income countries with universal health care: Australia, Canada, France, Germany, the Netherlands, New Zealand, Norway, Sweden, Switzerland and the United Kingdom. Because of the high cost of pharmaceutical drugs and the lack of universal health care, the United States was not included.
Researchers focused on 6 categories of widely used primary care drugs usually purchased at retail pharmacies rather than hospital pharmacies. These included hypertension treatments, pain medications (nonsteroidal anti-inflammatory drugs as well as opioids), cholesterol-lowering drugs, noninsulin diabetes treatments, gastrointestinal medications and antidepressants. They measured frequency of use of the medications by average number of days of therapy purchased per capita.
Medications for treating high blood pressure accounted for the largest number of days of therapy in all countries.
In the 5 countries with universal, single-payer coverage of prescription medications, the average per-person cost was $77. Average costs were $99 in the 4 countries with universal social insurance for prescription drugs and $158 in Canada, which has a mixed system of private and public financing. Higher costs of drugs and the mix of therapies chosen accounted for most of the cost differences between countries.
"The volume of therapy purchased in Canada was about the same as that in the comparator countries; however, Canadians spent an estimated $2.3 billion more than they would have in 2015 if these primary care treatments had had the same average cost per day in Canada as in the 9 comparator countries combined," writes Dr. Steven Morgan, School of Population and Public Health, University of British Columbia, with coauthors.
"Average expenditures are lower among single-payer financing systems, which appear to promote lower prices and selection of lower-cost treatment options within therapeutic categories," the study authors conclude.
Original publication
Other news from the department politics & laws
Most read news
More news from our other portals
Last viewed contents
Are the high prices of cancer drugs justified? - Does the cost correspond to the particular drug’s effectiveness in combating the disease?
Vetter Marks the Start of New Clinical Site Construction with Groundbreaking Ceremony - Vetter continues to expand in the US
A New Era Begins: BioSpring Builds High-Tech Manufacturing Facility for Pharmaceutical Nucleic Acid APIs
GEA invests EUR 80 million in a pharmaceutical technology center for freeze-drying systems in Germany - First product chambers in the “Factory of the Future”
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
ChatGPT grows insect-toxic genetically engineered plant - Blind spot in the EU draft law on genetic engineering
Commission launches new strategy to make Europe a global leader in life sciences by 2030
CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech - BioNTech’s acquisition of CureVac will be implemented as planned
Time out: We all need a three-day weekend - Researchers confirm health benefits
Ibidi Awarded With the German bAV Prize 2023
Using AI as an exam tutor - Artificial intelligence is set to help human examinees study more effectively
